Celldex Therapeutics Stock Performance
| CLDX Stock | USD 26.22 1.01 3.71% |
The firm shows a Beta (market volatility) of 1.49, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Celldex Therapeutics will likely underperform. At this point, Celldex Therapeutics has a negative expected return of -0.72%. Please make sure to confirm Celldex Therapeutics' value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Celldex Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Celldex Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.71) | Five Day Return (5.75) | Year To Date Return (35.12) | Ten Year Return (90.43) | All Time Return (97.01) |
Last Split Factor 1:15 | Dividend Date 2019-02-11 | Last Split Date 2019-02-11 |
1 | Disposition of 18375 shares by Wright Richard M. of Celldex Therapeutics at 22.48 subject to Rule 16b-3 | 09/23/2024 |
2 | Acquisition by Heath-chiozzi Margo of 2043 shares of Celldex Therapeutics at 9.0165 subject to Rule 16b-3 | 10/16/2024 |
3 | Celldex Therapeutics pulls back 6.1 percent this week, but still delivers shareholders fantastic 57 percent CAGR over 5 years | 10/28/2024 |
4 | Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/06/2024 |
5 | Wellington Management Group LLPs Strategic Acquisition in Celldex Therapeutics Inc | 11/08/2024 |
6 | Acquisition by Marucci Anthony S of 11500 shares of Celldex Therapeutics at 26.82 subject to Rule 16b-3 | 11/11/2024 |
7 | Celldex Therapeutics CEO Anthony Marucci buys 308,430 in stock | 11/12/2024 |
8 | FMR LLCs Strategic Reduction in Celldex Therapeutics Inc Shares | 11/13/2024 |
9 | Disposition of 10500 shares by Marino James J of Celldex Therapeutics subject to Rule 16b-3 | 11/18/2024 |
10 | Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a ... | 11/20/2024 |
11 | Celldex Therapeutics Stock Surges Amid Positive Institutional Ratings | 11/27/2024 |
| Begin Period Cash Flow | 29.4 M | |
| Free Cash Flow | -109.1 M |
Celldex |
Celldex Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,347 in Celldex Therapeutics on September 5, 2024 and sell it today you would lose (1,725) from holding Celldex Therapeutics or give up 39.68% of portfolio value over 90 days. Celldex Therapeutics is currently does not generate positive expected returns and assumes 3.6691% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Celldex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Celldex Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celldex Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Celldex Therapeutics, and traders can use it to determine the average amount a Celldex Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1961
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLDX |
Estimated Market Risk
| 3.67 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.72 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Celldex Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Celldex Therapeutics by adding Celldex Therapeutics to a well-diversified portfolio.
Celldex Therapeutics Fundamentals Growth
Celldex Stock prices reflect investors' perceptions of the future prospects and financial health of Celldex Therapeutics, and Celldex Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celldex Stock performance.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (16.34) % | ||||
| Current Valuation | 1.05 B | ||||
| Shares Outstanding | 66.34 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 2.21 X | ||||
| Price To Sales | 174.37 X | ||||
| Revenue | 6.88 M | ||||
| Gross Profit | (79.9 M) | ||||
| EBITDA | (139.03 M) | ||||
| Net Income | (141.43 M) | ||||
| Cash And Equivalents | 356.82 M | ||||
| Cash Per Share | 7.63 X | ||||
| Total Debt | 2.54 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.29 X | ||||
| Book Value Per Share | 11.85 X | ||||
| Cash Flow From Operations | (107.29 M) | ||||
| Earnings Per Share | (2.58) X | ||||
| Market Capitalization | 1.74 B | ||||
| Total Asset | 465.63 M | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 400.57 M | ||||
| Current Asset | 294.94 M | ||||
| Current Liabilities | 30.24 M | ||||
About Celldex Therapeutics Performance
Evaluating Celldex Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Celldex Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Celldex Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (104.04) | (98.84) | |
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.36) | (0.37) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.33) | (0.35) |
Things to note about Celldex Therapeutics performance evaluation
Checking the ongoing alerts about Celldex Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Celldex Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Celldex Therapeutics generated a negative expected return over the last 90 days | |
| Celldex Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.88 M. Net Loss for the year was (141.43 M) with loss before overhead, payroll, taxes, and interest of (79.9 M). | |
| Celldex Therapeutics currently holds about 356.82 M in cash with (107.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63. | |
| Celldex Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Celldex Therapeutics Stock Surges Amid Positive Institutional Ratings |
- Analyzing Celldex Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celldex Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Celldex Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Celldex Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celldex Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Celldex Therapeutics' stock. These opinions can provide insight into Celldex Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.